Access Consortium statement on COVID-19 vaccines evidence
This collective statement from medicine regulators from Australia, Canada, Singapore, Switzerland and the UK discusses the regulatory evidence requirements for COVID-19 vaccine approvals and considerations for post-market pharmacovigilance.
Source:
Medicines and Healthcare products Regulatory Agency
SPS commentary:
The Access Consortium regulatory authorities are collaborating to advance the regulatory science needed to support the rapid development of diagnostic tests, as well as vaccines and treatments against COVID-19.